메뉴 건너뛰기




Volumn 24, Issue 6, 2006, Pages 593-600

Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

Author keywords

Aggressive lymphoma; DHAP; Rituximab; Salvage treatment

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; RITUXIMAB;

EID: 33748871973     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600814490     Document Type: Article
Times cited : (50)

References (34)
  • 1
    • 0028115715 scopus 로고
    • A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study
    • Fisher, R.I.; Gaynor, E.R.; Dahlberg, S.; Oken, M.M.; Grogan, T.M.; et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann. Oncol. 1994, 5 (Suppl. 2), 91-95.
    • (1994) Ann. Oncol. , vol.5 , Issue.SUPPL. 2 , pp. 91-95
    • Fisher, R.I.1    Gaynor, E.R.2    Dahlberg, S.3    Oken, M.M.4    Grogan, T.M.5
  • 2
    • 0028790440 scopus 로고
    • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
    • Philip, T.; Guglielmi, C.; Hagenbeek, A.; Somers, R.; Van der Lelie, H.; et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 1995, 333 (23), 1540-1545.
    • (1995) N. Engl. J. Med. , vol.333 , Issue.23 , pp. 1540-1545
    • Philip, T.1    Guglielmi, C.2    Hagenbeek, A.3    Somers, R.4    Van Der Lelie, H.5
  • 3
    • 0029920432 scopus 로고    scopus 로고
    • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic groups
    • Prince, H.M.; Imrie, K.; Crump, M.; Stewart, A.K.; Girouard, C.; et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br. J. Haematol. 1996, 92 (4), 880-889.
    • (1996) Br. J. Haematol. , vol.92 , Issue.4 , pp. 880-889
    • Prince, H.M.1    Imrie, K.2    Crump, M.3    Stewart, A.K.4    Girouard, C.5
  • 4
    • 0028304010 scopus 로고
    • MINE-ESHAP salvage therapy for recurrent and refractory lymphomas
    • Cabanillas, F.; Rodriguez, M.A. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas. Semin. Hematol. 1994, 31 (2 Suppl. 3), 30.
    • (1994) Semin. Hematol. , vol.31 , Issue.2 SUPPL. 3 , pp. 30
    • Cabanillas, F.1    Rodriguez, M.A.2
  • 5
    • 0023818185 scopus 로고
    • Effective salvage therapy for lymphoma with cis-platin in combination with high-dose Ara-C and dexamethasone (DHAP)
    • Velasquez, W.S.; Cabanillas, F.; Salvador, P.; McLaughlin, P.; Fridrik, M.; et al. Effective salvage therapy for lymphoma with cis-platin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988, 71 (1), 117-122.
    • (1988) Blood , vol.71 , Issue.1 , pp. 117-122
    • Velasquez, W.S.1    Cabanillas, F.2    Salvador, P.3    McLaughlin, P.4    Fridrik, M.5
  • 6
    • 0032761285 scopus 로고    scopus 로고
    • Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
    • Moskowitz, C.H.; Bertino, J.R.; Glassman, J.R.; Hedrick, E.E.; Hunte, S.; et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 1999, 17 (12), 3776-3785.
    • (1999) J. Clin. Oncol. , vol.17 , Issue.12 , pp. 3776-3785
    • Moskowitz, C.H.1    Bertino, J.R.2    Glassman, J.R.3    Hedrick, E.E.4    Hunte, S.5
  • 7
    • 0029044083 scopus 로고
    • Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP
    • Rodriguez, M.A.; Cabanillas, F.C.; Velasquez, W.; Hagemeister, F.B.; McLaughlin, P.; et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J. Clin. Oncol. 1995, 13 (7), 1734-1741.
    • (1995) J. Clin. Oncol. , vol.13 , Issue.7 , pp. 1734-1741
    • Rodriguez, M.A.1    Cabanillas, F.C.2    Velasquez, W.3    Hagemeister, F.B.4    McLaughlin, P.5
  • 8
    • 0019379808 scopus 로고
    • Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine
    • Bergerat, J.P.; Drewinko, B.; Corry, P.; Barlogie, B.; Ho, D.H. Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1981, 41 (1), 25-30.
    • (1981) Cancer Res. , vol.41 , Issue.1 , pp. 25-30
    • Bergerat, J.P.1    Drewinko, B.2    Corry, P.3    Barlogie, B.4    Ho, D.H.5
  • 9
    • 0030886589 scopus 로고    scopus 로고
    • Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience
    • Rodriguez-Monge, E.J.; Cabanillas, F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol. Oncol. Clin. North Am. 1997, 11 (5), 937-947.
    • (1997) Hematol. Oncol. Clin. North Am. , vol.11 , Issue.5 , pp. 937-947
    • Rodriguez-Monge, E.J.1    Cabanillas, F.2
  • 10
    • 2542643822 scopus 로고    scopus 로고
    • Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: A low probability of cure
    • Jabbour, E.; Chalhoub, B.; Suzan, F.; Aloulou, S.; Cainap, C.; et al. Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk. Lymphoma 2004, 45 (7), 1391-1394.
    • (2004) Leuk. Lymphoma , vol.45 , Issue.7 , pp. 1391-1394
    • Jabbour, E.1    Chalhoub, B.2    Suzan, F.3    Aloulou, S.4    Cainap, C.5
  • 11
    • 1842368507 scopus 로고    scopus 로고
    • IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
    • Maloney, D.G.; Grillo-Lopez, A.J.; White, C.A.; Bodkin, D.; Schilder, R.J.; et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90 (6), 2188-2195.
    • (1997) Blood , vol.90 , Issue.6 , pp. 2188-2195
    • Maloney, D.G.1    Grillo-Lopez, A.J.2    White, C.A.3    Bodkin, D.4    Schilder, R.J.5
  • 12
    • 0033774970 scopus 로고    scopus 로고
    • Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines
    • Flieger, D.; Renoth, S.; Beier, I.; Sauerbruch, T.; Schmidt-Wolf, I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000, 204 (1), 55-63.
    • (2000) Cell Immunol. , vol.204 , Issue.1 , pp. 55-63
    • Flieger, D.1    Renoth, S.2    Beier, I.3    Sauerbruch, T.4    Schmidt-Wolf, I.5
  • 13
    • 0344766075 scopus 로고    scopus 로고
    • Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
    • Czuczman, M.S.; Grillo-Lopez, A.J.; White, C.A.; Saleh, M.; Gordon, L.; et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 1999, 17 (1), 268-276.
    • (1999) J. Clin. Oncol. , vol.17 , Issue.1 , pp. 268-276
    • Czuczman, M.S.1    Grillo-Lopez, A.J.2    White, C.A.3    Saleh, M.4    Gordon, L.5
  • 14
    • 0035863406 scopus 로고    scopus 로고
    • Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
    • Vose, J.M.; Link, B.K.; Grossbard, M.L.; Czuczman, M.; Grillo-Lopez, A.; et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 2001, 19 (2), 389-397.
    • (2001) J. Clin. Oncol. , vol.19 , Issue.2 , pp. 389-397
    • Vose, J.M.1    Link, B.K.2    Grossbard, M.L.3    Czuczman, M.4    Grillo-Lopez, A.5
  • 15
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    • Coiffier, B.; Lepage, E.; Briere, J.; Herbrecht, R.; Tilly, H.; et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002, 346 (4), 235-242.
    • (2002) N. Engl. J. Med. , vol.346 , Issue.4 , pp. 235-242
    • Coiffier, B.1    Lepage, E.2    Briere, J.3    Herbrecht, R.4    Tilly, H.5
  • 16
    • 0027444652 scopus 로고
    • A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
    • A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 1993, 329 (14), 987-994.
    • (1993) N. Engl. J. Med. , vol.329 , Issue.14 , pp. 987-994
  • 17
    • 0042449063 scopus 로고    scopus 로고
    • Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    • NCI Sponsored International Working Group
    • Cheson, B.D.; Horning, S.J.; Coiffier, B.; Shipp, M.A.; Fisher, R.I.; et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999, 17 (4), 1244.
    • (1999) J. Clin. Oncol. , vol.17 , Issue.4 , pp. 1244
    • Cheson, B.D.1    Horning, S.J.2    Coiffier, B.3    Shipp, M.A.4    Fisher, R.I.5
  • 18
    • 0028261089 scopus 로고
    • ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study
    • Velasquez, W.S.; McLaughlin, P.; Tucker, S.; Hagemeister, F.B.; Swan, F.; et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J. Clin. Oncol. 1994, 12 (6), 1169-1176.
    • (1994) J. Clin. Oncol. , vol.12 , Issue.6 , pp. 1169-1176
    • Velasquez, W.S.1    McLaughlin, P.2    Tucker, S.3    Hagemeister, F.B.4    Swan, F.5
  • 19
    • 0027182362 scopus 로고
    • EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma
    • Wilson, W.H.; Bryant, G.; Bates, S.; Fojo, A.; Wittes, R.E.; et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 1993, 11 (8), 1573-1582.
    • (1993) J. Clin. Oncol. , vol.11 , Issue.8 , pp. 1573-1582
    • Wilson, W.H.1    Bryant, G.2    Bates, S.3    Fojo, A.4    Wittes, R.E.5
  • 20
    • 1842829171 scopus 로고    scopus 로고
    • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    • Kewalramani, T.; Zelenetz, A.D.; Nimer, S.D.; Portlock, C.; Straus, D.; et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004, 103 (10), 3684-3688.
    • (2004) Blood , vol.103 , Issue.10 , pp. 3684-3688
    • Kewalramani, T.1    Zelenetz, A.D.2    Nimer, S.D.3    Portlock, C.4    Straus, D.5
  • 21
    • 79960970775 scopus 로고    scopus 로고
    • High response rate and complete remission rate achieved by adding rituximab to Taxol and topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma
    • Younes, A.; Mclauglin, P.; Hagemeister, F.B.; Pro, B.; Samaniego, F.; et al. High response rate and complete remission rate achieved by adding rituximab to Taxol and topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma. Blood 2001, 98 (11), 345a.
    • (2001) Blood , vol.98 , Issue.11
    • Younes, A.1    Mclauglin, P.2    Hagemeister, F.B.3    Pro, B.4    Samaniego, F.5
  • 22
    • 0036178668 scopus 로고    scopus 로고
    • The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R
    • Wilson, W.H.; Gutierrez, M.; O'Connor, P.; Frankel, S.; Jaffe, E.; et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin. Oncol. 2002, 29 (1 Suppl. 2), 41-47.
    • (2002) Semin. Oncol. , vol.29 , Issue.1 SUPPL. 2 , pp. 41-47
    • Wilson, W.H.1    Gutierrez, M.2    O'Connor, P.3    Frankel, S.4    Jaffe, E.5
  • 23
    • 1842555344 scopus 로고    scopus 로고
    • Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: Results of a phase II study
    • Jermann, M.; Jost, L.M.; Taverna, C.; Jacky, E.; Honegger, H.P.; et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann. Oncol. 2004, 15 (3), 511-516.
    • (2004) Ann. Oncol. , vol.15 , Issue.3 , pp. 511-516
    • Jermann, M.1    Jost, L.M.2    Taverna, C.3    Jacky, E.4    Honegger, H.P.5
  • 24
    • 0032533888 scopus 로고    scopus 로고
    • The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group
    • Blay, J.; Gomez, F.; Sebban, C.; Bachelot, T.; Biron, P.; et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998, 92 (10), 3562-3568.
    • (1998) Blood , vol.92 , Issue.10 , pp. 3562-3568
    • Blay, J.1    Gomez, F.2    Sebban, C.3    Bachelot, T.4    Biron, P.5
  • 25
    • 0026065050 scopus 로고
    • Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation
    • Press, O.W.; Livingston, R.; Mortimer, J.; Collins, C.; Appelbaum, F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J. Clin. Oncol. 1991, 9 (3), 423-431.
    • (1991) J. Clin. Oncol. , vol.9 , Issue.3 , pp. 423-431
    • Press, O.W.1    Livingston, R.2    Mortimer, J.3    Collins, C.4    Appelbaum, F.5
  • 26
    • 19944432350 scopus 로고    scopus 로고
    • A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma
    • Biagi, J.; Herbert, K.; Smith, C.; Abdi, E.; Leahy, M.; et al. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leuk. Lymphoma 2005, 46 (2), 197-206.
    • (2005) Leuk. Lymphoma , vol.46 , Issue.2 , pp. 197-206
    • Biagi, J.1    Herbert, K.2    Smith, C.3    Abdi, E.4    Leahy, M.5
  • 27
    • 0031757275 scopus 로고    scopus 로고
    • Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial
    • Guglielmi, C.; Gomez, F.; Philip, T.; Hagenbeek, A.; Martelli, M.; et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J. Clin. Oncol. 1998, 16 (10), 3264-3269.
    • (1998) J. Clin. Oncol. , vol.16 , Issue.10 , pp. 3264-3269
    • Guglielmi, C.1    Gomez, F.2    Philip, T.3    Hagenbeek, A.4    Martelli, M.5
  • 28
    • 0036256650 scopus 로고    scopus 로고
    • Treatment of relapsed aggressive lymphomas: Regimens with and without high-dose therapy and stem cell rescue
    • Hagemeister, F.B. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother. Pharmacol. 2002, 49 (Suppl. 1), S13-20.
    • (2002) Cancer Chemother. Pharmacol. , vol.49 , Issue.SUPPL. 1
    • Hagemeister, F.B.1
  • 29
    • 0031045771 scopus 로고    scopus 로고
    • Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas
    • Caballero, M.D.; Amigo, M.L.; Hernandez, J.M.; Vazquez, L.; del Canizo, C.; et al. Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. Ann. Hematol. 1997, 74 (2), 79-82.
    • (1997) Ann. Hematol. , vol.74 , Issue.2 , pp. 79-82
    • Caballero, M.D.1    Amigo, M.L.2    Hernandez, J.M.3    Vazquez, L.4    Del Canizo, C.5
  • 30
    • 0033955394 scopus 로고    scopus 로고
    • Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure?
    • Josting, A.; Reiser, M.; Rueffer, U.; Salzberger, B.; Diehl, V.; Engert, A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J. Clin. Oncol. 2000, 18 (2), 332-339.
    • (2000) J. Clin. Oncol. , vol.18 , Issue.2 , pp. 332-339
    • Josting, A.1    Reiser, M.2    Rueffer, U.3    Salzberger, B.4    Diehl, V.5    Engert, A.6
  • 31
    • 4644226626 scopus 로고    scopus 로고
    • Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma
    • Leo, E.; Scheuer, L.; Schmidt-Wolf, I.G.; Kerowgan, M.; Schmitt, C.; et al. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Eur. J. Haematol. 2004, 73 (4), 251-257.
    • (2004) Eur. J. Haematol. , vol.73 , Issue.4 , pp. 251-257
    • Leo, E.1    Scheuer, L.2    Schmidt-Wolf, I.G.3    Kerowgan, M.4    Schmitt, C.5
  • 32
    • 16544369964 scopus 로고    scopus 로고
    • Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma
    • Hoerr, A.L.; Gao, F.; Hidalgo, J.; Tiwari, D.; Blum, K.A.; et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 2004, 22 (22), 4561-4566.
    • (2004) J. Clin. Oncol. , vol.22 , Issue.22 , pp. 4561-4566
    • Hoerr, A.L.1    Gao, F.2    Hidalgo, J.3    Tiwari, D.4    Blum, K.A.5
  • 33
    • 0025896583 scopus 로고
    • Parma International protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation
    • Philip, T.; Chauvin, F.; Armitage, J.; Bron, D.; Hagenbeek, A.; et al. Parma International protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991, 77 (7), 1587-1592.
    • (1991) Blood , vol.77 , Issue.7 , pp. 1587-1592
    • Philip, T.1    Chauvin, F.2    Armitage, J.3    Bron, D.4    Hagenbeek, A.5
  • 34
    • 0038511330 scopus 로고    scopus 로고
    • Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma
    • Vose, J.; Sneller, V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann. Oncol. 2003, 14 (Suppl. 1), i17-20.
    • (2003) Ann. Oncol. , vol.14 , Issue.SUPPL. 1
    • Vose, J.1    Sneller, V.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.